Table 2.

Summary of testing methodologies and kinase gene coverage in published series of KFTC [15–42]

Study	Testing approach	Method	Cohort Size	No. with kinase fusions								% fusion-positive
				ALK	BRAF	MET	NTRK1	NTRK2	NTRK3	RET	ROS1
Adult papillary thyroid carcinoma
Musholt et al.	Consecutive	RT-PCR	119	-	-	-	15	-	-	17	-	27%
Brzeziańska et al.	Consecutive	RT-PCR	33	-	-	-	4	-	-	7	-	33%
Chou et al.	Consecutive	IHC, FISH	498	14	-	-	-	-	-	-	-	3%
Park et al.	Consecutive	IHC, FISH, NanoString	341	4	-	-	-	-	-	-	-	1%
Lu et al.	Consecutive	NGS	138	0	1	-	1	-	2	7	0	8%
Lee et al.	Consecutive	IHC, FISH, RT-PCR	769	0	-	-	3	-	-	16	-	2%
Bastos et al.	Consecutive	RT-PCR	116	4	0	-	-	-	6	-	-	9%
Liang et al.	Consecutive	NGS	355	1	1	0	3	0	9	30	0	12%
Panebianco et al.	Selective	NGS	na	27	-	-	-	-	-	-	-	-
Chu et al.	Selective	NGS	212	2	6	2	8	0	10	28	1	27%
Lee et al.	Consecutive	IHC, FISH, NGS	525	-	-	-	2	0	10	-	-	2%
Nozaki et al.	Consecutive	FISH	307	1	-	-	2	-	1	-	0	1%
Kong et al.	Consecutive	IHC, FISH	315	-	-	-	3	0	16	-	-	6%
Pediatric papillary thyroid carcinoma
Fenton et al.	Consecutive	RT-PCR	33	-	-	-	-	-	-	15	-	45%
Prasad et al.	Consecutive	NGS	27	0	0	0	1	-	6	6	-	48%
Cordioli et al.	Consecutive	RT-PCR	35	-	4	-	-	-	3	13	-	57%
Sisdelli et al.	Consecutive	RT-PCR, FISH	80	-	15	-	-	-	-	-	-	19%
Alzahrani et al.	Consecutive	NGS	48	1	0	0	1	0	5	14	0	44%
Pekova et al.	Consecutive	NGS	93	6	2	1	3	0	14	26	0	56%
Lee et al.	Consecutive	NGS, IHC, FISH	106	6	0	0	2	0	2	20	0	28%
Macerola et al.	Consecutive	NanoString	163	6	0	-	5	-	18	17	-	28%
Rogounovitch et al.	Consecutive	RT-PCR	34	-	0	-	-	-	6	12	-	53%
Franco et al.	Consecutive	NGS	131	0	1	2	4	0	5	34	0	35%
Ricarte-Filho et al.	Selective	NGS	144	-	-	-	7	0	13	-	-	14%
Radiation-associated papillary thyroid carcinoma
Bounacer et al.	Consecutive	RT-PCR	15	-	-	-	2	-	-	-	-	13%
Rabes et al.	Consecutive	RT-PCR	191	-	-	-	2	-	-	38	-	21%
Dinets et al.	Consecutive	RT-PCR	70	-	-	-	-	-	-	24	-	34%
Efanov et al.	Consecutive	NGS	65	5	7	0	2	0	7	22	0	66%
Poorly differentiated thyroid carcinoma
Landa et al.	Selective	NGS	84	3	0	0	0	0	0	5	0	10%
Panebianco et al.	Selective	NGS	na	5	-	-	-	-	-	-	-	-
Duan et al.	Consecutive	NGS	41	1	0	-	1	-	-	6	-	20%
Chu et al.	Selective	NGS	23	1	0	0	0	0	0	1	0	9%
Pekova et al.	Consecutive	NGS	10	-	-	-	1	0	1	-	-	20%
Anaplastic thyroid carcinoma
Duan et al.	Consecutive	NGS	25	0	0	-	1	-	-	0	-	4%
Chu et al.	Selective	NGS	39	0	0	0	0	0	0	2	0	5%
Nozaki et al.	Consecutive	FISH	16	0	-	-	1	-	0	-	0	6%
Xu et al.	Consecutive	NGS	360	0	0	0	1	1	0	2	0	1%